Immutep (ASX:IMM) Preferred Dividends : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Immutep's preferred dividends for the three months ended in Dec. 2023 was A$0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Immutep Preferred Dividends Historical Data

The historical data trend for Immutep's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Preferred Dividends Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Preferred Dividends

Get a 7-Day Free Trial

Immutep Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Immutep Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Immutep (ASX:IMM) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Immutep (ASX:IMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines